



### Amendments to the Claims

**1. (Original)** A compound represented by the formula (I):




wherein





represents a 8- to 10-membered fused heterocyclic ring; R<sup>1</sup> represents (1) a hydrogen atom, (2) a halogen atom, (3) a cyano group, (4) an oxo group, (5) an optionally protected hydroxy group, (6) an optionally protected carboxyl group, (7) an optionally protected amino group, (8) a cyclic group which may have a substituent(s), (9) an aliphatic hydrocarbon group which may have a substituent(s), or (10) an optionally protected thiol group; n represents 0 or an integer of 1 to 8; provided that if n represents an integer of not less than 2, the plural R<sup>1</sup>'s are the same or different;  
or a salt thereof, a solvate thereof or a prodrug thereof.


**2. (Original)** The compound according to claim 1, wherein




is



or




**3. (Original)** The compound according to claim 1, wherein the formula (I) is represented by the formula (I-1):




wherein R<sup>2</sup> represents an optionally protected amino group or a cyclic group which may have a substituent(s); R<sup>3</sup> represents a halogen atom, an optionally protected hydroxy group, an optionally protected thiol group or a cyclic group which may have a substituent(s); R<sup>4</sup> represents a hydrogen atom, a halogen atom, an optionally protected amino group, an optionally protected hydroxy group, an optionally protected thiol group, a cyclic group which may have a substituent(s) or an aliphatic hydrocarbon group which may have a substituent(s); m represents 0 or an integer of 1 to 3; provided that if m represents an integer of not less than 2, the plural R<sup>4</sup>'s are the same or different.

**4. (Currently amended)** The compound according to claim 1, wherein the formula (I) is represented by the formula (I-2):



wherein p represents 0 or an integer of 1 to 5; the other symbols represent the same meanings as in claim 3. R<sup>2</sup> represents an optionally protected amino group or a cyclic group which may have a substituent(s); R<sup>3</sup> represents a halogen atom, an optionally protected hydroxy group, an optionally protected thiol group or a cyclic group which may have a substituent(s); R<sup>4</sup> represents a hydrogen atom, a halogen atom, an optionally protected amino group, an optionally protected hydroxy group, an optionally protected thiol group, a cyclic group which may have a substituent(s) or an aliphatic hydrocarbon group which may have a substituent(s); p represents 0 or an integer of 1 to 5; provided that if p represents an integer of not less than 2, the plural R<sup>4</sup>'s are the same or different.

**5. (Currently amended)** The compound according to claim 1, wherein the formula (I) is represented by the formula (I-3):



wherein all the symbols represent the same meanings as in claim 3 or 4  $R^2$  represents an optionally protected amino group or a cyclic group which may have a substituent(s);  $R^4$  represents a hydrogen atom, a halogen atom, an optionally protected amino group, an optionally protected hydroxy group, an optionally protected thiol group, a cyclic group which may have a substituent(s) or an aliphatic hydrocarbon group which may have a substituent(s); p represents 0 or an integer of 1 to 5; provided that if p represents an integer of not less than 2, the plural  $R^4$ 's are the same or different.

**6. (Currently amended)** The compound according to claim 3, 4, or 5, wherein  $R^2$  is a protected amino group.

**7. (Original)** The compound according to claim 1 selected from the group consisting of

- (1) N-(1,3-benzodioxol-5-ylmethyl)-5-chloropyrazolo[1,5-a]pyrimidin-7-amine,
- (2) 5-chloro-N-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (3) 5-thien-3-yl-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (4) N-(4-{7-[(4-methoxybenzyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl}phenyl)acetamide,
- (5) 2-{4-[(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl}ethanol,
- (6) 5-(2-furyl)-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (7) 5-(4-fluorophenyl)-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (8) 5-(5-methylthien-2-yl)-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (9) 5-(3,4-dimethylphenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (10) N-(pyridin-4-ylmethyl)-5-quinolin-3-ylpyrazolo[1,5-a]pyrimidin-7-amine,
- (11) 5-(3-fluorophenyl)-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,

- (12) N-(pyridin-4-ylmethyl)-5-thien-3-ylpyrazolo[1,5-a]pyrimidin-7-amine,
- (13) N-(4-methoxybenzyl)-5-thien-3-ylpyrazolo[1,5-a]pyrimidin-7-amine,
- (14) 1-(3-{7-[(4-methoxybenzyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl}phenyl)ethanone,
- (15) 5-pyridin-4-yl-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (16) N<sup>5</sup>-[4-(dimethylamino)phenyl]-N<sup>7</sup>-propylpyrazolo[1,5-a]pyrimidin-5,7-diamine,
- (17) 5-(3-furyl)-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (18) 5-(3-furyl)-N-(thien-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (19) 5-(3-furyl)-N-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (20) 5-(4-methylphenyl)-N-(4-pyridinylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (21) 5-(3-methoxyphenyl)-N-(4-pyridinylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (22) 5-(3-furyl)-N-(4-pyridinylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (23) N-(4-methoxybenzyl)-5-(4-methylphenyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (24) N-(4-methoxybenzyl)-5-(3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (25) 5-(3-furyl)-N-(4-methoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (26) {1-[5-(3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl}methanol,
- (27) 5-(4-methyl-2-thienyl)-N-(4-pyridinylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (28) 4-[(3-chloro-4-fluorophenyl)amino]-6-methyl-2H-chromen-2-one,
- (29) 4-[(3-chloro-4-fluorophenyl)amino]-8-methyl-2H-chromen-2-one,
- (30) 4-[(3-chloro-4-fluorophenyl)amino]-2H-chromen-2-one,
- (31) 5-chloro-N-(4-methoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (32) 5-chloro-N-(4-methoxybenzyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-amine,
- (33) 5-chloro-N-(4-methoxybenzyl)-3-methylpyrazolo[1,5-a]pyrimidin-7-amine,
- (34) N-(4-methoxybenzyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-amine,
- (35) N-(4-methoxybenzyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine,
- (36) N-(4-methoxybenzyl)-3,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine,
- (37) N-(4-methoxybenzyl)-5-phenylpyrazolo[1,5-a]pyrimidin-7-amine,
- (38) N-(4-methoxybenzyl)-2-methyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-amine, and
- (39) N-(4-methoxybenzyl)-3-methyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-amine.




**8. (Original)** A pharmaceutical composition which comprises the compound represented by the formula (I) according to claim 1, a salt thereof, a solvate thereof, or a prodrug thereof.

**9. (Original)** The pharmaceutical composition according to claim 8, which is a kinase inhibitor.

**10. (Original)** The pharmaceutical composition according to claim 9, wherein the kinase is c-Jun N-terminal kinase.

**11. (Original)** The pharmaceutical composition according to claim 10, wherein the c-Jun N-terminal kinase is JNK1.

**12. (Currently amended)** The pharmaceutical composition according to claim 8, wherein the compound is represented by the formula (I-1), (I-2), or (I-3):



wherein all the symbols represent the same meanings as in claim 3 or 4 R<sup>2</sup> represents an optionally protected amino group or a cyclic group which may have a substituent(s); R<sup>3</sup> represents a halogen atom, an optionally protected hydroxy group, an optionally

protected thiol group or a cyclic group which may have a substituent(s); R<sup>4</sup> represents a hydrogen atom, a halogen atom, an optionally protected amino group, an optionally protected hydroxy group, an optionally protected thiol group, a cyclic group which may have a substituent(s) or an aliphatic hydrocarbon group which may have a substituent(s); m represents 0 or an integer of 1 to 3; provided that if m represents an integer of not less than 2, the plural R<sup>4</sup>'s are the same or different; p represents 0 or an integer of 1 to 5; provided that if p represents an integer of not less than 2, the plural R<sup>4</sup>'s are the same or different.

**13. (Original)** The composition according to claim 8, wherein the compound is selected from the group consisting of

- (1) N-(1,3-benzodioxol-5-ylmethyl)-5-chloropyrazolo[1,5-a]pyrimidin-7-amine,
- (2) 5-chloro-N-(3-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (3) 5-thien-3-yl-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (4) N-(4-{7-[{(4-methoxybenzyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl}phenyl)acetamide,
- (5) 2-{4-[(5-chloropyrazolo[1,5-a]pyrimidin-7-yl)amino]phenyl}ethanol,
- (6) 5-(2-furyl)-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (7) 5-(4-fluorophenyl)-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (8) 5-(5-methylthien-2-yl)-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (9) 5-(3,4-dimethylphenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (10) N-(pyridin-4-ylmethyl)-5-quinolin-3-ylpyrazolo[1,5-a]pyrimidin-7-amine,
- (11) 5-(3-fluorophenyl)-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (12) N-(pyridin-4-ylmethyl)-5-thien-3-ylpyrazolo[1,5-a]pyrimidin-7-amine,
- (13) N-(4-methoxybenzyl)-5-thien-3-ylpyrazolo[1,5-a]pyrimidin-7-amine,
- (14) 1-(3-{7-[{(4-methoxybenzyl)amino]pyrazolo[1,5-a]pyrimidin-5-yl}phenyl)ethanone,
- (15) 5-pyridin-4-yl-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (16) N<sup>5</sup>-[4-(dimethylamino)phenyl]-N<sup>7</sup>-propylpyrazolo[1,5-a]pyrimidin-5,7-diamine,
- (17) 5-(3-furyl)-N-(3,4,5-trimethoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,
- (18) 5-(3-furyl)-N-(thien-2-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine,

- (19) 5-(3-furyl)-N-(3,4,5-trimethoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-amine,  
(20) 5-(4-methylphenyl)-N-(4-pyridinylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine,  
(21) 5-(3-methoxyphenyl)-N-(4-pyridinylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine,  
(22) 5-(3-furyl)-N-(4-pyridinylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine,  
(23) N-(4-methoxybenzyl)-5-(4-methylphenyl)pyrazolo[1,5-a]pyrimidin-7-amine,  
(24) N-(4-methoxybenzyl)-5-(3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-amine,  
(25) 5-(3-furyl)-N-(4-methoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,  
(26) {1-[5-(3-methoxyphenyl)pyrazolo[1,5-a]pyrimidin-7-yl]-2-pyrrolidinyl}methanol,  
(27) 5-(4-methyl-2-thienyl)-N-(4-pyridinylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine,  
(28) 4-[(3-chloro-4-fluorophenyl)amino]-6-methyl-2H-chromen-2-one,  
(29) 4-[(3-chloro-4-fluorophenyl)amino]-8-methyl-2H-chromen-2-one,  
(30) 4-[(3-chloro-4-fluorophenyl)amino]-2H-chromen-2-one, (31) 5-chloro-N-(4-methoxybenzyl)pyrazolo[1,5-a]pyrimidin-7-amine,  
(32) 5-chloro-N-(4-methoxybenzyl)-2-methylpyrazolo[1,5-a]pyrimidin-7-amine,  
(33) 5-chloro-N-(4-methoxybenzyl)-3-methylpyrazolo[1,5-a]pyrimidin-7-amine,  
(34) N-(4-methoxybenzyl)-5-methylpyrazolo[1,5-a]pyrimidin-7-amine,  
(35) N-(4-methoxybenzyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine,  
(36) N-(4-methoxybenzyl)-3,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amine,  
(37) N-(4-methoxybenzyl)-5-phenylpyrazolo[1,5-a]pyrimidin-7-amine,  
(38) N-(4-methoxybenzyl)-2-methyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-amine, and  
(39) N-(4-methoxybenzyl)-3-methyl-5-phenylpyrazolo[1,5-a]pyrimidin-7-amine.

**14. (Original)** The pharmaceutical composition according to claim 10, which is a preventive and/or therapeutic agent for c-Jun N-terminal kinase-mediated diseases.

**15. (Original)** The pharmaceutical composition according to claim 14, wherein the c-Jun N-terminal kinase-mediated diseases are metabolic diseases or inflammatory diseases.

**16. (Original)** The pharmaceutical composition according to claim 15, wherein the metabolic disease is diabetes mellitus.

**17. (Original)** The pharmaceutical composition according to claim 16, wherein the diabetes mellitus is insulin-resistant diabetes mellitus.

**18. (Original)** The pharmaceutical composition according to claim 15, wherein the inflammatory diseases are osteitis.

**19. (Original)** The pharmaceutical composition according to claim 18, wherein the osteitis is arthritis.

**20. (Original)** A method for inhibiting c-Jun N-terminal kinase, which comprises administering to a mammal an effective amount of the compound according to claim 1, a salt thereof, a solvate thereof or a prodrug thereof.

**21. (Original)** A method for preventing and/or treating c-Jun N-terminal kinase-mediated diseases in a mammal, which comprises administering to a mammal an effective amount of the compound according to claim 1, a salt thereof, a solvate thereof or a prodrug thereof.

**22. (Original)** Use of the compound according to claim 1, a salt thereof, a solvate thereof or a prodrug thereof, for the manufacture of a preventive and/or therapeutic agent for c-Jun N-terminal kinase-mediated diseases.

**23. (Original)** A pharmaceutical composition which comprises a combination of the compound according to claim 1, a salt thereof, a solvate thereof or a prodrug thereof and one or two or more medicaments selected from the group consisting of an MTP inhibitor, an HMG-CoA reductase inhibitor, a squalene synthetase inhibitor, a fibrate preparation, an ACAT inhibitor, a 5-lipoxygenase inhibitor, a cholesterol absorption inhibitor, a bile acid absorption inhibitor, a ileum  $\text{Na}^+$ /bile acid cotransporter inhibitor, an LDL receptor activator/expression enhancer, a lipase inhibitor, a probucol preparation, a nicotinic acid preparation, a hypoglycemic sulfonylurea agent, a biguanide preparation, an  $\alpha$ -glucosidase inhibitor, a rapid-acting insulin secretagogue, an insulin preparation, a

DPP4 inhibitor, a PTP1B inhibitor, a  $\beta$ 3 adrenoceptor agonist, a PPAR agonist, and a therapeutic agent for diabetes complications.